PMG
REGN icon

ProVise Management Group’s Regeneron Pharmaceuticals REGN Stock Holding History

ProVise Management Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,486
Closed -$1.31M – 334
2023
Q4 		$1.31M Buy
1,486
+47
+3% +$38.7K 0.11% 156
2023
Q3 		$1.18M Buy
+1,439
New +$1.13M 0.11% 155
2020
Q3 		– Sell
-848
Closed -$529K – 303
2020
Q2 		$529K Buy
+848
New +$481K 0.08% 180
2020
Q1 		– Sell
-610
Closed -$229K – 295
2019
Q4 		$229K Buy
+610
New +$205K 0.03% 276

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ProVise Management Group's REGN Position: Q1 2024 in Review

ProVise Management Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 1,486 shares — an estimated $1.31M sold.

ProVise Management Group first reported a position in REGN in Q4 2019 and held it in 4 quarters. The position peaked at $1.31M in Q4 2023. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • ProVise Management Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • ProVise Management Group sold 1,486 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $1.31M.
  • ProVise Management Group first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • ProVise Management Group's Regeneron Pharmaceuticals position peaked at $1.31M in Q4 2023.
  • 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on ProVise Management Group's 13F filing for Q1 2024, filed 9 May 2024.